Archives: PDF

To compare the short-term treatment outcome of the 577 nm subthreshold micropulse laser (SML) and half-dose photodynamic therapy (PDT) in patients with chronic central serous chorioretinopathy (cCSC) and persistent subretinal fluid (SRF).

There are numerous reasons to use a laser when we are treating retinal disorders, and there are numerous lasers from which to choose. Most of us have experience with the green 532 nm lasers.

Laser photocoagulation has been the mainstay of treatment for diabetic macular edema (DME), but the introduction of the anti-VEGF drugs have led some to think laser is no longer an appropriate option. After an analysis of some of the clinical trials on the anti-VEGFs, it becomes apparent that laser is still widely used.

To understand MicroPulse laser technology, we must first understand conventional photocoagulation. In the latter, the laser beam is constantly “on” and its energy is absorbed by pigmented structures.

Central serous chorioretinopathy (CSC) is characterized by vision loss due to a serous detachment of the neurosensory retina. Clinical evidence from multimodal imaging, such as choroidal congestion and thickening and hyperpermeability of the choroid...

Retinal laser photocoagulation has been the mainstay of treatment for various retinal and macular diseases for many years. In addition, the quest for better visual outcomes and the minimization of side effects has resulted in the development of new, improved photocoagulation systems.

Laser photocoagulation is a common treatment for diabetic macular edema but not without side effects and can damage the neurosensory retina. Sub-threshold micropulse laser produces therapeutic effects without inducing detectable clinical visible changes.